These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
4. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related]
5. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V F1000Res; 2020; 9():576. PubMed ID: 32802318 [No Abstract] [Full Text] [Related]
6. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK mBio; 2020 Dec; 11(6):. PubMed ID: 33310780 [TBL] [Abstract][Full Text] [Related]
7. Withanone from Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804 [TBL] [Abstract][Full Text] [Related]
8. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
9. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269 [TBL] [Abstract][Full Text] [Related]
10. Interfacial Water in the SARS Spike Protein: Investigating the Interaction with Human ACE2 Receptor and In Vitro Uptake in A549 Cells. Singh AV; Kayal A; Malik A; Maharjan RS; Dietrich P; Thissen A; Siewert K; Curato C; Pande K; Prahlad D; Kulkarni N; Laux P; Luch A Langmuir; 2022 Jul; 38(26):7976-7988. PubMed ID: 35736838 [TBL] [Abstract][Full Text] [Related]
11. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis. Baig AM; Khaleeq A; Syeda H J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788 [TBL] [Abstract][Full Text] [Related]
12. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing SARS-CoV-2 by dimeric side chain-to-side chain cross-linked ACE2 peptide mimetics. Zhang YN; Zhang Y; Su S; Zhu HY; Xu W; Wang L; Wu M; Chen K; Yu FQ; Xi TK; Zhou Q; Xie YH; Qin X; Ge H; Lu L; Qing J; Fang GM Chem Commun (Camb); 2022 Feb; 58(11):1804-1807. PubMed ID: 35040445 [TBL] [Abstract][Full Text] [Related]
15. Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2. Sakib MMH; Nishat AA; Islam MT; Raihan Uddin MA; Iqbal MS; Bin Hossen FF; Ahmed MI; Bashir MS; Hossain T; Tohura US; Saif SI; Jui NR; Alam M; Islam MA; Hasan MM; Sufian MA; Ali MA; Islam R; Hossain MA; Halim MA Comput Biol Med; 2021 Sep; 136():104759. PubMed ID: 34403938 [TBL] [Abstract][Full Text] [Related]
17. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
18. The structural basis of accelerated host cell entry by SARS-CoV-2†. Seyran M; Takayama K; Uversky VN; Lundstrom K; Palù G; Sherchan SP; Attrish D; Rezaei N; Aljabali AAA; Ghosh S; Pizzol D; Chauhan G; Adadi P; Mohamed Abd El-Aziz T; Soares AG; Kandimalla R; Tambuwala M; Hassan SS; Azad GK; Pal Choudhury P; Baetas-da-Cruz W; Serrano-Aroca Á; Brufsky AM; Uhal BD FEBS J; 2021 Sep; 288(17):5010-5020. PubMed ID: 33264497 [TBL] [Abstract][Full Text] [Related]
19. Venomous gland transcriptome and venom proteomic analysis of the scorpion Androctonus amoreuxi reveal new peptides with anti-SARS-CoV-2 activity. Ghazal A; Clarke D; Abdel-Rahman MA; Ribeiro A; Collie-Duguid E; Pattinson C; Burgoyne K; Muhammad T; Alfadhel S; Heidari Z; Samir R; Gerges MM; Nkene I; Colamarino RA; Hijazi K; Houssen WE Peptides; 2024 Mar; 173():171139. PubMed ID: 38142817 [TBL] [Abstract][Full Text] [Related]
20. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2. Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]